📰 Forward Looking Statements News
Page 49 - Forward Looking Statements News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Forward Looking Statements. Real-time updates on events, politics, business and more.
February 24, 2024
RE/MAX Holdings, Inc. (NYSE:RMAX) Q4 2023 Earnings Call Transcript February 23, 2024 RE/MAX Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the RE/MAX Holdings Fourth Quarter and Full Year Earnings 2023 Earnings Conference […]
February 24, 2024
American Homes 4 Rent (NYSE:AMH) Q4 2023 Earnings Call Transcript February 23, 2024 American Homes 4 Rent isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the AMH Fourth Quarter 2023 Earnings Conference Call. At this time, […]
February 23, 2024
HIGHLIGHTS: Montage Gold adds to its leadership team as it embarks on becoming a leading African gold mining company Martino De Ciccio appointed as CEO to lead the Company's next strategic phase Peder Olsen appointed as Chief Development Officer, to... - Veroeffentlicht am 23.02.2024
February 23, 2024
Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation Priority Review granted based on positive results from two Phase 3 trialsIf approved,...
February 23, 2024
Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in more than a decade Regulatory submissions are also under review in China and Europe Dupixent is the leading biologic treatment for all five of its FDA-approved indications in new-to-brand prescriptions in the U.S. TARRYTOWN, N.Y. and PARIS, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,
February 23, 2024
Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for
February 23, 2024
Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in...
February 23, 2024
ABIDJAN, Cote d'Ivoire, Feb. 23, 2024 - Montage Gold Corp. is pleased to announce that the non-brokered private placement financing announced on February 22, 2024 has been increased to 50,000,000 common shares of the Company at a price of C$0.70 per... - Veroeffentlicht am 23.02.2024
February 23, 2024
Copart, Inc. (NASDAQ:CPRT) Q2 2024 Earnings Call Transcript February 22, 2024 Copart, Inc. misses on earnings expectations. Reported EPS is $0.33 EPS, expectations were $0.35. CPRT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and welcome to […]
February 23, 2024
ICON Public Limited Company (NASDAQ:ICLR) Q4 2023 Earnings Call Transcript February 22, 2024 ICON Public Limited Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the ICON Q4 and Full […]